Supported online self-management versus care as usual for symptoms of fatigue, pain and urgency/incontinence in adults with inflammatory bowel disease (IBD-BOOST): study protocol for a randomised controlled trial.


Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
03 Aug 2021
Historique:
received: 14 11 2020
accepted: 16 07 2021
entrez: 4 8 2021
pubmed: 5 8 2021
medline: 6 8 2021
Statut: epublish

Résumé

Despite being in clinical remission, many people with inflammatory bowel disease (IBD) live with fatigue, chronic abdominal pain and bowel urgency or incontinence that limit their quality of life. We aim to test the effectiveness of an online self-management programme (BOOST), developed using cognitive behavioural principles and a theoretically informed logic model, and delivered with facilitator support. In people with IBD who report symptoms of fatigue, pain or urgency and express a desire for intervention, does a facilitator-supported tailored (to patient needs) online self-management programme for fatigue, pain and faecal urgency/incontinence improve IBD-related quality of life (measured using the UK-IBDQ) and global rating of symptom relief (0-10 scale) compared with care as usual? A pragmatic two-arm, parallel group randomised controlled trial (RCT), of a 12-session facilitator-supported online cognitive behavioural self-management programme versus care as usual to manage symptoms of fatigue, pain and faecal urgency/incontinence in IBD. Patients will be recruited through a previous large-scale survey of unselected people with inflammatory bowel disease. The UK Inflammatory Bowel Disease Questionnaire and global rating of symptom relief at 6 months are the co-primary outcomes, with multiple secondary outcomes measured also at 6 and 12 months post randomisation to assess maintenance. The RCT has an embedded pilot study, health economics evaluation and process evaluation. We will randomise 680 patients, 340 in each group. Demographic characteristics and outcome measures will be presented for both study groups at baseline. The UK-IBDQ and global rating of symptom relief at 6 and 12 months post randomisation will be compared between the study groups. The BOOST online self-management programme for people with IBD-related symptoms of fatigue, pain and urgency has been designed to be easily scalable and implemented. If it is shown to improve patients' quality of life, this trial will enable clinicians and patients to make informed management decisions. This is the first trial, to our knowledge, focused on multiple symptoms prioritised by both people with IBD and health professionals. ISRCTN71618461 . Registered on 9 September 2019.

Sections du résumé

BACKGROUND BACKGROUND
Despite being in clinical remission, many people with inflammatory bowel disease (IBD) live with fatigue, chronic abdominal pain and bowel urgency or incontinence that limit their quality of life. We aim to test the effectiveness of an online self-management programme (BOOST), developed using cognitive behavioural principles and a theoretically informed logic model, and delivered with facilitator support.
PRIMARY RESEARCH QUESTION UNASSIGNED
In people with IBD who report symptoms of fatigue, pain or urgency and express a desire for intervention, does a facilitator-supported tailored (to patient needs) online self-management programme for fatigue, pain and faecal urgency/incontinence improve IBD-related quality of life (measured using the UK-IBDQ) and global rating of symptom relief (0-10 scale) compared with care as usual?
METHODS METHODS
A pragmatic two-arm, parallel group randomised controlled trial (RCT), of a 12-session facilitator-supported online cognitive behavioural self-management programme versus care as usual to manage symptoms of fatigue, pain and faecal urgency/incontinence in IBD. Patients will be recruited through a previous large-scale survey of unselected people with inflammatory bowel disease. The UK Inflammatory Bowel Disease Questionnaire and global rating of symptom relief at 6 months are the co-primary outcomes, with multiple secondary outcomes measured also at 6 and 12 months post randomisation to assess maintenance. The RCT has an embedded pilot study, health economics evaluation and process evaluation. We will randomise 680 patients, 340 in each group. Demographic characteristics and outcome measures will be presented for both study groups at baseline. The UK-IBDQ and global rating of symptom relief at 6 and 12 months post randomisation will be compared between the study groups.
DISCUSSION CONCLUSIONS
The BOOST online self-management programme for people with IBD-related symptoms of fatigue, pain and urgency has been designed to be easily scalable and implemented. If it is shown to improve patients' quality of life, this trial will enable clinicians and patients to make informed management decisions. This is the first trial, to our knowledge, focused on multiple symptoms prioritised by both people with IBD and health professionals.
TRIAL REGISTRATION BACKGROUND
ISRCTN71618461 . Registered on 9 September 2019.

Identifiants

pubmed: 34344432
doi: 10.1186/s13063-021-05466-4
pii: 10.1186/s13063-021-05466-4
pmc: PMC8329619
doi:

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

516

Subventions

Organisme : National Institute for Health Research
ID : RP-PG-0216-20001

Informations de copyright

© 2021. The Author(s).

Références

Gut. 1999 Jan;44(1):77-80
pubmed: 9862829
Gut. 2010 Dec;59(12):1652-61
pubmed: 21071584
Eur J Gastroenterol Hepatol. 2014 Aug;26(8):910-7
pubmed: 24942954
Ann Behav Med. 2013 Aug;46(1):81-95
pubmed: 23512568
Gastroenterology. 2018 Jul;155(1):47-57
pubmed: 29702118
J Crohns Colitis. 2013 Sep;7(8):e302-11
pubmed: 23228710
J Clin Epidemiol. 2000 Mar 1;53(3):297-306
pubmed: 10760641
J Psychosom Res. 2013 Aug;75(2):103-12
pubmed: 23915765
J Psychosom Res. 2015 Jan;78(1):12-24
pubmed: 25438982
Health Technol Assess. 2016 Jun;20(44):1-320
pubmed: 27329657
Aliment Pharmacol Ther. 2004 Jul 1;20(1):89-97
pubmed: 15225175
J Psychosom Res. 2013 Aug;75(2):113-20
pubmed: 23915766
BMC Gastroenterol. 2013 Apr 21;13:68
pubmed: 23602047
J Crohns Colitis. 2016 Jul;10(7):860-9
pubmed: 26802088
Patient Educ Couns. 2002 Jul;47(3):257-63
pubmed: 12088604
BMJ. 2008 Sep 29;337:a1655
pubmed: 18824488
Aliment Pharmacol Ther. 2015 Jul;42(2):203-11
pubmed: 25989464
Am J Psychiatry. 1997 Mar;154(3):408-14
pubmed: 9054791
Behav Res Ther. 2012 Jun;50(6):415-21
pubmed: 22516321
Inflamm Bowel Dis. 2013 Sep;19(10):2111-7
pubmed: 23883959
J Crohns Colitis. 2014 Aug;8(8):835-44
pubmed: 24491516
Eur J Gastroenterol Hepatol. 2020 Mar;32(3):335-344
pubmed: 31851083
Res Involv Engagem. 2016 Aug 20;2:29
pubmed: 29507764
Behav Res Ther. 2021 Feb;137:103464
pubmed: 31780252
BMJ. 2002 May 18;324(7347):1183
pubmed: 12016181
Psychol Med. 2010 Jan;40(1):85-94
pubmed: 19531276
Inflamm Bowel Dis. 2013 Jun;19(7):1450-62
pubmed: 23624884
Trials. 2017 May 11;18(1):213
pubmed: 28490349
J Wound Ostomy Continence Nurs. 2001 May;28(3):156-68
pubmed: 11337702
BMJ. 2015 Mar 19;350:h1258
pubmed: 25791983
Med Care. 1999 Jan;37(1):5-14
pubmed: 10413387
Trials. 2015 Oct 06;16:444
pubmed: 26445224
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
J Psychosom Res. 2006 Jun;60(6):631-7
pubmed: 16731240
J Crohns Colitis. 2014 Nov;8(11):1398-406
pubmed: 24856864
J Psychosom Res. 2006 Nov;61(5):583-5
pubmed: 17084134
Cochrane Database Syst Rev. 2014 Feb 26;(2):CD010152
pubmed: 24574082
Gastroenterology. 2003 Nov;125(5):1320-9
pubmed: 14598248
Aliment Pharmacol Ther. 2017 Jul;46(2):115-125
pubmed: 28470846
Lancet Gastroenterol Hepatol. 2019 Nov;4(11):863-872
pubmed: 31492643
J Wound Ostomy Continence Nurs. 2004 Mar-Apr;31(2):85-94
pubmed: 15209431
Implement Sci. 2008 Oct 13;3:44
pubmed: 18851743
Arthritis Care Res. 1993 Dec;6(4):213-22
pubmed: 7918717
Inflamm Bowel Dis. 2016 Jan;22(1):171-81
pubmed: 26360545
Psychosom Med. 2008 Feb;70(2):205-13
pubmed: 18256342
Eff Clin Pract. 2001 Nov-Dec;4(6):256-62
pubmed: 11769298
Dis Colon Rectum. 2008 Apr;51(4):436-42
pubmed: 18219532
Health Psychol. 2007 Jul;26(4):464-72
pubmed: 17605566
Gut. 2014 Jul;63(7):1092-102
pubmed: 24107590
Gut. 2019 Sep;68(9):1613-1623
pubmed: 30971419
J Consult Clin Psychol. 2013 Apr;81(2):251-62
pubmed: 22730954
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Res Involv Engagem. 2015 Aug 7;1:8
pubmed: 29062497
Eur J Neurol. 2015 Nov;22(11):1443-52
pubmed: 26177836
J Adv Nurs. 2013 Sep;69(9):1987-99
pubmed: 23215959
Gut. 2004 Nov;53(11):1639-45
pubmed: 15479685
Cochrane Database Syst Rev. 2015 Mar 23;(3):CD011118
pubmed: 25803793

Auteurs

Christine Norton (C)

King's College London, 57 Waterloo Road, London, SE1 8WA, UK. Christine.norton@kcl.ac.uk.

Jonathan Syred (J)

King's College London, 57 Waterloo Road, London, SE1 8WA, UK.

Sally Kerry (S)

Pragmatic Clinical Trials Unit, Queen Mary University of London, 58 Turner St, Whitechapel, London, E1 2AB, UK.

Micol Artom (M)

NHS Digital, Skipton House, 80 London Road, London, SE1 6LH, UK.

Louise Sweeney (L)

Health Psychology Section, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Ailsa Hart (A)

IBD Unit, St Mark's Hospital, Watford Road, Harrow, HA13UJ, UK.

Wladyslawa Czuber-Dochan (W)

King's College London, 57 Waterloo Road, London, SE1 8WA, UK.

Stephanie J C Taylor (SJC)

Institute of Population Health Sciences, Queen Mary University of London, 58 Turner St, Whitechapel, London, E1 2AB, UK.

Borislava Mihaylova (B)

Institute of Population Health Sciences, Queen Mary University of London, 58 Turner St, Whitechapel, London, E1 2AB, UK.
Nuffield Department of Population Health, University of Oxford, Old Road Campus, Oxford, OX3 7LF, UK.

Chris Roukas (C)

Institute of Population Health Sciences, Queen Mary University of London, 58 Turner St, Whitechapel, London, E1 2AB, UK.

Qasim Aziz (Q)

Centre for Neuroscience, Surgery and Trauma, Blizard Institute, Wingate Institute of Neurogastroenterology, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, 26 Ashfield Street, London, E1 2AJ, UK.

Laura Miller (L)

Pragmatic Clinical Trials Unit, Queen Mary University of London, 58 Turner St, Whitechapel, London, E1 2AB, UK.

Richard Pollok (R)

Department of Gastroenterology, St George's University Hospitals NHS Foundation Trust and St George's University of London, London, SW17 0QT, UK.

Sonia Saxena (S)

Department of Primary Care and Public Health Imperial College London, London, UK.

Imogen Stagg (I)

London North West University Hospitals, Watford Road, Harrow, HA1 3UJ, UK.

Helen Terry (H)

Crohn's & Colitis UK, 1 Bishops Square (Helios Court), Hatfield Business Park, Hatfield, Hertfordshire, AL10 9NE, UK.

Zohra Zenasni (Z)

Pragmatic Clinical Trials Unit, Queen Mary University of London, 58 Turner St, Whitechapel, London, E1 2AB, UK.

Lesley Dibley (L)

School of Health Sciences, Faculty of Education, Health and Human Sciences, University of Greenwich, (Avery Hill Campus), London, SE9 2UG, UK.

Rona Moss-Morris (R)

Psychology Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH